Exploring lymphocyte subsets in COVID-19 patients: insights from a tertiary academic medical center with a high proportion of patients on immunosuppression
2024

Lymphocyte Subsets in COVID-19 Patients

Sample size: 103 publication 10 minutes Evidence: moderate

Author Information

Author(s): Daenen Katrijn, van Hooijdonk Samantha, Tong-Minh Kirby, Dik Willem A., van Hagen Petrus M., Huijben Jilske A., Gommers Diederik, van Gorp Eric C. M., Endeman Henrik, Dalm Virgil A. S. H.

Primary Institution: Erasmus University Medical Center

Hypothesis

Differences in lymphocyte subsets are associated with severe or fatal COVID-19 disease.

Conclusion

Lymphocyte subsets were not significantly different between SARS-CoV-2 negative and positive patients and between mild versus severe cases.

Supporting Evidence

  • Twenty-five SARS-CoV-2 negative and 77 SARS-CoV-2 positive patients were included.
  • 57 patients had mild COVID-19 and 20 had severe COVID-19.
  • Prior use of immunosuppressive drugs was not associated with COVID-19 severity.

Takeaway

The study looked at blood cells in COVID-19 patients to see if they could predict how sick someone might get, but found no clear differences.

Methodology

Patients were included from the emergency department, and lymphocyte subsets were analyzed within 24 hours of presentation.

Potential Biases

The study may not fully represent the most severe cases due to exclusion criteria.

Limitations

Patients directly transferred to ICU were excluded, potentially omitting the most critically ill.

Participant Demographics

The majority of patients were male, with a mean age of 58 years.

Statistical Information

P-Value

p<0.05

Confidence Interval

0.355-3.194

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1436637

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication